‘Amazing’ trial shows drug combination stops lung cancer advancing for longer
Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months Doctors are hailing “amazing” trial results that show a new drug combination stopped lung cancer advancing for more than 40% longer than the standard treatment. Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8…